Keeler Thomas Management LLC Makes New Investment in IDEXX Laboratories, Inc. $IDXX

Keeler Thomas Management LLC acquired a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the 3rd quarter, according to its most recent disclosure with the SEC. The fund acquired 1,771 shares of the company’s stock, valued at approximately $925,000.

Several other institutional investors have also added to or reduced their stakes in IDXX. Bank of New York Mellon Corp acquired a new position in IDEXX Laboratories in the 2nd quarter worth $628,223,000. Arrowstreet Capital Limited Partnership increased its holdings in IDEXX Laboratories by 52.4% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 838,839 shares of the company’s stock worth $471,335,000 after purchasing an additional 288,471 shares in the last quarter. International Assets Investment Management LLC raised its stake in shares of IDEXX Laboratories by 30,484.1% in the 3rd quarter. International Assets Investment Management LLC now owns 234,274 shares of the company’s stock valued at $122,336,000 after purchasing an additional 233,508 shares during the period. Alyeska Investment Group L.P. raised its stake in shares of IDEXX Laboratories by 97.3% in the 2nd quarter. Alyeska Investment Group L.P. now owns 401,082 shares of the company’s stock valued at $211,146,000 after purchasing an additional 197,808 shares during the period. Finally, American Capital Management Inc. acquired a new stake in shares of IDEXX Laboratories in the 2nd quarter valued at about $85,341,000. 87.84% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

IDXX has been the topic of a number of research reports. Jefferies Financial Group cut their price target on IDEXX Laboratories from $795.00 to $705.00 and set a “buy” rating on the stock in a report on Tuesday, October 20th. Leerink Partners decreased their price objective on IDEXX Laboratories from $725.00 to $715.00 and set an “outperform” rating for the company in a report on Monday, July 13th. KeyCorp began coverage on IDEXX Laboratories in a report on Monday, October 12th. They set a “sector weight” rating for the company. UBS Group dropped their target price on IDEXX Laboratories from $670.00 to $627.00 and set a “neutral” rating on the stock in a research report on Tuesday, October 27th. Finally, Citigroup boosted their target price on IDEXX Laboratories from $650.00 to $670.00 and gave the company a “neutral” rating in a research note on Wednesday, August 5th. Eight investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, IDEXX Laboratories currently has an average rating of “Moderate Buy” and a consensus price target of $721.67.

More IDEXX Laboratories News

Here are the key news stories impacting IDEXX Laboratories this week:

• Positive Sentiment: Q3 earnings and revenue beat estimates. IDEXX reported adjusted earnings of approximately $3.96–$3.98 per share versus the $3.71 consensus estimate. Revenue rose about 10% year over year to $1.21 billion, exceeding expectations of roughly $1.19 billion. IDEXX Laboratories Q3 earnings report
• Positive Sentiment: Recurring diagnostics remained the key growth engine. Recurring diagnostic revenue to veterinarians increased about 11%, demonstrating continued demand for IDEXX’s testing platforms and supporting the company’s earnings growth despite softer veterinary visit trends. IDEXX raises forecast
• Positive Sentiment: Management raised its full-year 2026 earnings and revenue guidance. The revised outlook suggests that IDEXX expects diagnostics growth, operating performance and customer adoption of its offerings to offset weakness in veterinary visit volumes. The guidance increase was the primary catalyst behind the strong stock reaction. IDEXX revises 2026 earnings guidance
• Neutral Sentiment: The earnings call reinforced a favorable long-term growth narrative. Management highlighted continued expansion in diagnostics, recurring revenue and productivity initiatives, which may support durable growth but also leaves the stock reliant on sustained premium valuation expectations. IDEXX Laboratories earnings call highlights
• Negative Sentiment: Margin trends and veterinary demand remain risks. Some reports noted that the higher profit forecast was not driven by stronger testing demand, while the margin outlook softened. Weak veterinary visits could pressure near-term volume growth if diagnostics expansion does not continue. IDEXX sales and margin outlook

Insiders Place Their Bets

In other IDEXX Laboratories news, Director Lawrence D. Kingsley sold 2,203 shares of the company’s stock in a transaction on Friday, September 4th. The shares were sold at an average price of $532.08, for a total transaction of $1,172,172.24. Following the sale, the director directly owned 9,568 shares of the company’s stock, valued at approximately $5,090,941.44. This represents a 18.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 0.79% of the company’s stock.

IDEXX Laboratories Trading Up 21.8%

Shares of IDEXX Laboratories stock opened at $671.64 on Tuesday. IDEXX Laboratories, Inc. has a 12-month low of $500.61 and a 12-month high of $769.98. The stock has a market cap of $52.91 billion, a P/E ratio of 47.23 and a beta of 1.55. The company has a quick ratio of 0.87, a current ratio of 1.17 and a debt-to-equity ratio of 0.19. The business’s 50 day moving average is $536.56 and its 200-day moving average is $573.88.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Monday, November 2nd. The company reported $3.96 EPS for the quarter, beating the consensus estimate of $3.71 by $0.25. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%. The company had revenue of $1.21 billion during the quarter, compared to the consensus estimate of $1.19 billion. During the same quarter in the prior year, the firm posted $3.22 EPS. The firm’s revenue for the quarter was up 9.9% compared to the same quarter last year. Equities research analysts predict that IDEXX Laboratories, Inc. will post 14.81 earnings per share for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.

IDEXX’s companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.